Login to Your Account

Introgen Takes a Hit on FDA's Refusal to Review Gene Therapy

By Donna Young

Wednesday, September 3, 2008
Shares of Introgen Therapeutics Inc. plummeted 38.7 percent Tuesday after the firm said the FDA refused to accept the biologics license application for its gene therapy Advexin as a treatment of recurrent, refractory head and neck cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription